MEDOVEX CORP. (NASDAQ:MDVX) Files An 8-K Entry into a Material Definitive AgreementItem 1.01 Entry Into A Material Definitive Agreement
On February 26, 2018, MedoveX Corporation (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with selected accredited investors (each an “Investor” and collectively, the “Investors”). to the terms of the Securities Purchase Agreement, the Company sold an aggregate of 770,000 shares of Common Stock and 385,000 Warrants to purchase Common Stock (the “Offering”). The Offering resulted in $308,000 in gross proceeds to the Company. The Warrants have a five year term commencing six (6) months from issuance and an exercise price of $0.75. The shares were sold at $0.40 per share. The Warrants are exercisable on a cashless basis in the event that the underlying shares are not subject to an effective registration statement. The Shares of Common Stock sold in the Offering were registered in the Company’s effective registration statement on Form S-3 (Reg No. 333-217411). The foregoing description of the terms of the Securities Purchase Agreement and Warrant is not complete and is qualified in it’s entirety by the full text of the Securities Purchase Agreement and Warrant, which are filed as Exhibit 10.1 and 10.2 to the Current Report on Form 8-K and are incorporated by reference herein.
Each of the Investors is an “accredited investor” as such term is defined in Rule 501 of Regulation D promulgated under the Securities Act of 1933, as amended (the “Act”), and the warrants were sold to them in reliance on the exemption from registration provided by Rule 506 and Section 4(2) of the Act.
Item 3.02 Unregistered Sales of Equity Securities.
See Item 1.01 above, with respect to the sale of the Warrants.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
Medovex Corp. ExhibitEX-10.1 2 ex10-1.htm SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February ___,…To view the full exhibit click here
